SKAN GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.5 CHF | -0.86% |
|
-0.62% | -0.37% |
| May. 31 | Skan Group Boosts Interest in Belgian Unit Aseptic Technologies to 90% | MT |
| Mar. 26 | Transcript : SKAN Group AG, 2023 Earnings Call, Mar 26, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.41 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.37% | 2B | - | ||
| +75.69% | 12.57B | B- | ||
| -24.68% | 7.34B | C+ | ||
| +6.22% | 6.61B | C- | ||
| +12.58% | 5.39B | D+ | ||
| +26.90% | 4.53B | - | ||
| -21.14% | 3.91B | B- | ||
| -22.99% | 2.91B | C | ||
| +47.42% | 2.37B | C- | ||
| +6.21% | 1.91B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SKAN Stock
- Ratings SKAN Group AG
